The pathway analyses of activin A targets common to both cell lines revealed that activin A treatment significantly upregulated pluripotency, cancer, TGF-β, Notch, p53, and Hippo signalling pathways (Figure 2A). The gene discussed is TGFB1; the disease is cancer.